Loading
Pneumococcal Vaccines / Vaccines, Conjugate / Pneumococcal Infections · Journal article
Expert Review of Vaccines · June 19, 2026
A consensus or society position rather than new primary data.
This expert consensus statement synthesizes post-pandemic epidemiologic changes in invasive pneumococcal disease across Latin America and the Caribbean, highlighting resurgence driven by vaccination gaps and disrupted healthcare systems. The authors recommend strengthening vaccination infrastructure and timely adoption of higher-valency pneumococcal conjugate vaccines, but the statement is not grounded in new quantitative primary data and does not report effect sizes or incidence comparisons.
Journal article. Latin America and Caribbean region; children at risk for invasive pneumococcal disease. Latin America and the Caribbean.
COVID-19 pandemic initially reduced IPD incidence through non-pharmaceutical interventions Subsequent relaxation of restrictions coupled with immunization gaps led to resurgence of pneumococcal infections Emergence of non-vaccine serotypes causing IPD documented post-pandemic
COVID-19 pandemic initially reduced IPD incidence through non-pharmaceutical interventions
Clinicians and public health professionals in Latin America should use this consensus to advocate for restoration of robust vaccination programs, completion of booster doses in the second year of life, and timely adoption of higher-valency PCVs. The statement emphasizes addressing vaccination infrastructure gaps and health communication to counter pandemic-related setbacks.
Expert consensus statement synthesizing regional surveillance data and literature to guide post-pandemic pneumococcal vaccination policy in Latin America, but without new primary data or quantified efficacy evidence.
As stated by the source record.
Clinicians and public health professionals in Latin America should use this consensus to advocate for restoration of robust vaccination programs, completion of booster doses in the second year of life, and timely adoption of higher-valency PCVs. The statement emphasizes addressing vaccination infrastructure gaps and health communication to counter pandemic-related setbacks.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Introduction. The Latin American Society of Pediatric Infectious Diseases (SLIPE) convened a multidisciplinary expert panel to assess the post-pandemic epidemiology of invasive pneumococcal disease (IPD) in Latin America and the Caribbean. The COVID-19 pandemic initially reduced IPD incidence due to non-pharmaceutical interventions, but subsequent relaxation of restrictions, coupled with immunization gaps, led to a resurgence of pneumococcal infections. The consensus statement reviews literature and regional surveillance data to analyze how disrupted vaccination programs, socioeconomic inequities, and weakened healthcare systems amplified the regional vulnerability to vaccine-preventable diseases.Areas covered. This document addresses epidemiologic changes in IPD following the pandemic, the interplay between respiratory viral infections and pneumococcal disease, trends in pneumococcal conjugate vaccine (PCV) coverage and related barriers, and the emergence of non-vaccine serotypes causing IPD.Expert opinion. Sustaining herd protection in the region requires strengthening vaccination infrastructure, restoring confidence through effective communication, and ensuring the completion of booster doses in the second year of life. Despite limited serotype data, countries should prioritize the timely adoption of higher-valency PCVs in feasible schedules to mitigate the growing burden of pneumococcal disease and prevent further setbacks in child health.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.